摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二氯-5-甲基氟苯磺酰氯 | 28286-86-4

中文名称
2,4-二氯-5-甲基氟苯磺酰氯
中文别名
2,4-二氯-5-甲基氟苯磺酰氯;2,4-二氯-5-甲基苯磺酰氯;2,4-二氯-5-甲基苯磺酰氯,97%
英文名称
2,4-dichloro-5-methyl-benzenesulfonyl chloride
英文别名
2,4-Dichloro-5-methylbenzenesulfonyl chloride
2,4-二氯-5-甲基氟苯磺酰氯化学式
CAS
28286-86-4
化学式
C7H5Cl3O2S
mdl
MFCD00044016
分子量
259.541
InChiKey
DFBKCDYLPLBSJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    67-72 °C
  • 沸点:
    333.2±42.0 °C(Predicted)
  • 密度:
    1.560±0.06 g/cm3(Predicted)
  • 稳定性/保质期:
    如果遵照规格使用和储存,则不会分解,未有已知危险反应。避免与氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    42.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    8
  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2904909090
  • 危险品运输编号:
    1760
  • 包装等级:
    II
  • 危险类别:
    8

SDS

SDS:663df94a4c9d68bdd2b70ebddf557f9c
查看
Name: 2 4-Dichloro-5-methylbenzenesulfonyl chloride Material Safety Data Sheet
Synonym: m-Toluenesulfonyl chloride, 4,6-dichloro-; 2,4-Dichlorotoluene-5-sulfochloride
CAS: 28286-86-4
Section 1 - Chemical Product MSDS Name:2 4-Dichloro-5-methylbenzenesulfonyl chloride Material Safety Data Sheet
Synonym:m-Toluenesulfonyl chloride, 4,6-dichloro-; 2,4-Dichlorotoluene-5-sulfochloride

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
28286-86-4 2,4-Dichloro-5-methylbenzenesulfonyl c > 95 248-938-1
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Do not get water inside containers.

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Do not allow contact with water. Use only in a chemical fume hood. Discard contaminated shoes. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store protected from moisture.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 28286-86-4: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 67-72 deg C
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H5Cl3O2S
Molecular Weight: 259.54

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Moisture sensitive. Material hydrolyzes in contact with moisture/water releasing toxic and corrosive fumes of hydrogen chloride and aqueous hydrochloric acid.
Conditions to Avoid:
Dust generation, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 28286-86-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,4-Dichloro-5-methylbenzenesulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 28286-86-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 28286-86-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 28286-86-4 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,4-二氯-5-甲基氟苯磺酰氯四苯基溴化膦 potassium fluoride 作用下, 以 环丁砜 为溶剂, 反应 4.0h, 以77%的产率得到2,4-Difluoro-5-methyl-benzenesulfonyl fluoride
    参考文献:
    名称:
    四苯基溴化溴催化的氯芳基磺酰氯的“ Halex”氟化
    摘要:
    通过使用溴化四苯基phenyl作为催化剂,发现氯芳基磺酰氯衍生物与喷雾干燥的氟化钾的卤素交换有效地进行。氟芳基磺酰基衍生物的随后的磺酰化在酸性条件下容易得到氟代芳族化合物。
    DOI:
    10.1016/s0022-1139(00)82362-3
  • 作为产物:
    描述:
    2,4-二氯甲苯氯磺酸 作用下, 以 氯仿 为溶剂, 以70 %的产率得到2,4-二氯-5-甲基氟苯磺酰氯
    参考文献:
    名称:
    受天然产物启发发现三甲氧基苯基-1,2,4-三唑磺酰胺作为有效的微管蛋白聚合抑制剂
    摘要:
    一种独特的受天然产物启发的策略使得能够发现三甲氧基苯基-1,2,4-三唑并磺酰胺作为潜在的微管蛋白聚合抑制剂。开发了化学和区域选择性合成方法。化合物16被发现是微管蛋白聚合的有效抑制剂。它使细胞停滞在 G2/M 阶段并诱导多核细胞的形成,最终导致细胞死亡。
    DOI:
    10.1002/cmdc.202300562
点击查看最新优质反应信息

文献信息

  • [EN] SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS<br/>[FR] DERIVES DE XANTHINE SUBSTITUES PAR DES SULFONAMIDES ET UTILES COMME INHIBITEURS DE PEPCK
    申请人:HOFFMANN LA ROCHE
    公开号:WO2004074288A1
    公开(公告)日:2004-09-02
    The present invention is concerned with sulfonamide substituted xanthine derivatives of formula (I) or a pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.
    本发明涉及式(I)的磺酰胺取代的黄嘌呤衍生物或其药用可接受的盐或前药,其中R1、R2和R3如说明书中所定义。式(I)的化合物及其药用可接受的盐或前药作为糖异生调节剂显示出活性。
  • Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC)
    作者:Wentian Wang、Lu Zhang、Lorraine Morlock、Noelle S. Williams、Jerry W. Shay、Jef K. De Brabander
    DOI:10.1021/acs.jmedchem.9b00532
    日期:2019.5.23
    small-molecule-based therapies available that specifically target colorectal cancer (CRC) development and progression, the second leading cause of cancer deaths. We previously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (TASIN-1), a small molecule that specifically targets colorectal cancer cells lines with truncating mutations in the adenomatous polyposis
    尽管靶向抗癌疗法取得了进展,但仍没有针对小分子结肠直肠癌(CRC)发育和进程的小分子疗法,这是导致癌症死亡的第二大原因。我们先前披露了截短性腺瘤性结肠炎(APC)选择性抑制剂1(TASIN-1)的发现,这是一种小分子,可通过抑制腺瘤性息肉病(APC)肿瘤抑制基因中的截短突变而特异性靶向结直肠癌细胞系胆固醇的生物合成。在这里,我们报告了TASIN类似物的集合及其对结肠癌细胞系和等基因细胞系对活性的报告,报告了APC依赖选择性的状态。鉴定出许多有效的和选择性的类似物,包括具有良好代谢稳定性和药代动力学特性的化合物。本文报道的化合物代表了首个基因型选择性系列,该系列特异性靶向大多数CRC患者中存在的apc突变,并充当结肠癌靶向治疗的翻译平台。
  • Sulfonamide derivatives as 5-HT7 receptor antagonists
    申请人:SmithKline Beecham p.l.c.
    公开号:US06660751B1
    公开(公告)日:2003-12-09
    The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1 is halogen, hydroxy, C1-6alkyl, CF3, OCF3 or C1-6alkoxy; m is 0, 1, 2 or 3; R2 is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2 subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3 is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6 or COR6 where p is 0, 1 or 2 and R4, R5 and R6 are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.
    该发明涉及具有5-HT7受体拮抗活性的新型磺胺类化合物,其制备方法,含有它们的组合物以及它们在治疗中枢神经系统和其他疾病中的用途。 其中: Q为苯基或噻吩基; R1为卤素、羟基、C1-6烷基、三氟甲基、OCF3或C1-6烷氧基; m为0、1、2或3; R2为C1-4烷基; X为碳或CH, 当X为氮或CH时,为单键, 当X为碳时,为双键, D为单键、C═O、O或CH2,但当X为氮时,D不是氧; P为含有1至3个氧、氮和硫杂原子的5或6元杂芳基环,或者含有1至3个氧、氮和硫杂原子的苯并杂芳基环; R3为C1-6烷基,可选择地被NR4R5、芳基、芳基C1-6烷基、C1-6烷氧基、C1-6烷基硫基、氰基、羟基、硝基、卤素、三氟甲基、C2F5、NR4R5、CONR4R5、NR4COR5、S(O)pNR4R5、CHO、OCF3、SCF3、CH2OR6、CO2R6或COR6取代,其中p为0、1或2,R4、R5和R6独立地为氢、C1-6烷基、芳基或芳基C1-6烷基; n为0、1、2或3。
  • 11B-HSD1 inhibitors for the treatment of diabetes
    申请人:Amrien Kurt
    公开号:US20050288308A1
    公开(公告)日:2005-12-29
    Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    化合物的公式(I): 以及其药学上可接受的盐和酯,其中R1至R5具有权利要求1中给定的含义,可以用于制成药物组合物。
  • Aryl sulfonyl piperidines
    申请人:Gillespie Paul
    公开号:US20060199816A1
    公开(公告)日:2006-09-07
    Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    本文提供了以下式(1)的化合物: 以及其药学上可接受的盐,其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐